Vasoconstrictive properties of the 5HT1B/1D agonists: response to Dahlöf and Mathew.
D
D
Goldstein
D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D044302:Receptor, Serotonin, 5-HT1B; D044346:Receptor, Serotonin, 5-HT1D; D011985:Receptors, Serotonin / Q000187:drug effects*; D012307:Risk Factors; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D018170:Sumatriptan / Q000009:adverse effects / Q000627:therapeutic use; D014363:Tryptamines; D014662:Vasoconstrictor Agents / Q000009:adverse effects / Q000627:therapeutic use*
C470302:HTR1B protein, human; D007211:Indoles; D010880:Piperidines; D044302:Receptor, Serotonin, 5-HT1B; D044346:Receptor, Serotonin, 5-HT1D; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; D014662:Vasoconstrictor Agents; D018170:Sumatriptan; C106783:naratriptan